JP2011527667A5 - - Google Patents

Download PDF

Info

Publication number
JP2011527667A5
JP2011527667A5 JP2011513994A JP2011513994A JP2011527667A5 JP 2011527667 A5 JP2011527667 A5 JP 2011527667A5 JP 2011513994 A JP2011513994 A JP 2011513994A JP 2011513994 A JP2011513994 A JP 2011513994A JP 2011527667 A5 JP2011527667 A5 JP 2011527667A5
Authority
JP
Japan
Prior art keywords
methyl
tetrahydro
methoxy
pyrimido
ylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2011513994A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011527667A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2009/057144 external-priority patent/WO2009153197A1/en
Publication of JP2011527667A publication Critical patent/JP2011527667A/ja
Publication of JP2011527667A5 publication Critical patent/JP2011527667A5/ja
Abandoned legal-status Critical Current

Links

JP2011513994A 2008-06-18 2009-06-10 ハロ置換ピリミドジアゼピン Abandoned JP2011527667A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7338808P 2008-06-18 2008-06-18
US61/073,388 2008-06-18
PCT/EP2009/057144 WO2009153197A1 (en) 2008-06-18 2009-06-10 Halo-substituted pyrimidodiazepines as plkl inhibitors

Publications (2)

Publication Number Publication Date
JP2011527667A JP2011527667A (ja) 2011-11-04
JP2011527667A5 true JP2011527667A5 (https=) 2012-08-02

Family

ID=41431858

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011513994A Abandoned JP2011527667A (ja) 2008-06-18 2009-06-10 ハロ置換ピリミドジアゼピン

Country Status (4)

Country Link
US (1) US8003785B2 (https=)
EP (1) EP2303889A1 (https=)
JP (1) JP2011527667A (https=)
WO (1) WO2009153197A1 (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009042711A1 (en) 2007-09-25 2009-04-02 Takeda Pharmaceutical Company Limited Polo-like kinase inhibitors
EP2361242B1 (en) 2008-10-17 2018-08-01 Oryzon Genomics, S.A. Oxidase inhibitors and their use
WO2010084160A1 (en) 2009-01-21 2010-07-29 Oryzon Genomics S.A. Phenylcyclopropylamine derivatives and their medical use
SG179206A1 (en) * 2009-09-25 2012-04-27 Vertex Pharma Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors
RU2602814C2 (ru) 2009-09-25 2016-11-20 Оризон Дженомикс С.А. Лизинспецифические ингибиторы деметилазы-1 и их применение
CA2773827A1 (en) 2009-09-25 2011-03-31 Vertex Pharmaceuticals Incorporated Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors
US8946296B2 (en) 2009-10-09 2015-02-03 Oryzon Genomics S.A. Substituted heteroaryl- and aryl-cyclopropylamine acetamides and their use
JP5504898B2 (ja) * 2010-01-08 2014-05-28 セントラル硝子株式会社 ジフルオロシクロプロパン化合物の製造方法
WO2011106573A2 (en) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae
WO2011106574A2 (en) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Inhibitors for antiviral use
RS55348B1 (sr) 2010-04-19 2017-03-31 Oryzon Gnomics S A Inhibitori lizin specifične demetilaze-1 i njihova upotreba
EP2598480B1 (en) 2010-07-29 2019-04-24 Oryzon Genomics, S.A. Cyclopropylamine derivatives useful as lsd1 inhibitors
WO2012013728A1 (en) 2010-07-29 2012-02-02 Oryzon Genomics S.A. Arylcyclopropylamine based demethylase inhibitors of lsd1 and their medical use
US9061966B2 (en) 2010-10-08 2015-06-23 Oryzon Genomics S.A. Cyclopropylamine inhibitors of oxidases
WO2012072713A2 (en) 2010-11-30 2012-06-07 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae
WO2012107498A1 (en) 2011-02-08 2012-08-16 Oryzon Genomics S.A. Lysine demethylase inhibitors for myeloproliferative disorders
MX356344B (es) 2011-10-20 2018-05-23 Oryzon Genomics Sa Compuestos de (hetero)arilciclopropilamina como inhibidores de lsd1.
RU2668952C2 (ru) 2011-10-20 2018-10-05 Оризон Дженомикс, С.А. (гетеро)арилциклопропиламины в качестве ингибиторов lsd1
US8975398B2 (en) 2012-05-11 2015-03-10 Abbvie Inc. NAMPT inhibitors
AU2014292888B2 (en) 2013-07-25 2018-03-22 Dana-Farber Cancer Institute, Inc. Inhibitors of transcription factors and uses thereof
WO2015117087A1 (en) 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
CA2936865A1 (en) 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Diaminopyrimidine benzenesulfone derivatives and uses thereof
CN106715437A (zh) 2014-08-08 2017-05-24 达纳-法伯癌症研究所股份有限公司 二氮杂环庚烷衍生物及其用途
CN105646398B (zh) * 2014-12-05 2018-09-07 上海医药工业研究院 N-((1r,4r)-4-(4-(环丙基甲基)哌嗪-1-基)环己基)乙酰胺的制备方法
US10702527B2 (en) 2015-06-12 2020-07-07 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
HK1256417A1 (zh) 2015-09-11 2019-09-20 达纳-法伯癌症研究所股份有限公司 氰基噻吩并三唑并二氮杂环庚三烯及其用途
RU2018112953A (ru) 2015-09-11 2019-10-14 Дана-Фарбер Кэнсер Инститьют, Инк. Ацетамидтиенотриазолодиазепины и пути их применения
MX2018006499A (es) 2015-11-25 2018-08-01 Dana Farber Cancer Inst Inc Inhibidores de bromodominio bivalentes y usos de los mismos.
US20230158158A1 (en) * 2020-03-27 2023-05-25 Uppthera Pyrazolo quinazoline derivative compounds inducing selective degradation of plk1
WO2022145989A1 (ko) * 2020-12-31 2022-07-07 (주) 업테라 선택적 plk1 억제제로서의 피리미도디아제핀 유도체
EP4157849A4 (en) * 2021-08-10 2024-12-11 Uppthera, Inc. NOVEL PLK1 DEGRADATION-INDUCING COMPOUND
GB202313514D0 (en) 2023-09-05 2023-10-18 Cambridge Entpr Ltd Treatment of inflammatory diseases

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL354241A1 (en) 1999-09-17 2003-12-29 Abbott Gmbh & Co.Kgabbott Gmbh & Co.Kg Kinase inhibitors as therapeutic agents
US6806272B2 (en) 2001-09-04 2004-10-19 Boehringer Ingelheim Pharma Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
PT1427730E (pt) 2001-09-04 2006-11-30 Boehringer Ingelheim Pharma Novas di-hidropteridinonas, processo para sua preparação e sua utilização como medicamento
TW200804389A (en) 2006-02-14 2008-01-16 Vertex Pharma Dihydrodiazepines useful as inhibitors of protein kinases
TW200808325A (en) 2006-07-06 2008-02-16 Astrazeneca Ab Novel compounds
WO2008113711A1 (en) 2007-03-22 2008-09-25 F. Hoffmann-La Roche Ag Substituted pyrimidodiazepines useful as plk1 inhibitors
WO2009042711A1 (en) 2007-09-25 2009-04-02 Takeda Pharmaceutical Company Limited Polo-like kinase inhibitors

Similar Documents

Publication Publication Date Title
JP2011527667A5 (https=)
JP2019104748A5 (https=)
JP2011528658A5 (https=)
JP2008530099A5 (https=)
JP2013519684A5 (https=)
JP2010155827A5 (https=)
RU2009142434A (ru) Производные триазолопиридин-карбоксамидов и триазолопиримидин-карбоксамидов, их получение и их применение в терапии
JP2017504635A5 (https=)
RU2009142431A (ru) Производные триазолопиридинкарбоксамидов и триазолопиримидинкарбоксамидов, их получение и их применение в терапии
JP2012508252A5 (https=)
JP2011513305A5 (https=)
JP2013542218A5 (https=)
JP2012502067A5 (https=)
JP2021522262A5 (https=)
JP2012512863A5 (https=)
JP2012531433A5 (https=)
JP2012504608A5 (https=)
JP2009516727A5 (https=)
JP2009161540A5 (https=)
WO2009156861A3 (en) Substituted pyrimidone derivatives
WO2010089510A3 (fr) Dérivés d'azaspiranyl-alkylcarbamates d'hétérocycles à 5 chaînons, leur préparation et leur application en thérapeutique
JP2010504344A5 (https=)
JP2012516355A5 (https=)
JP2013540712A5 (https=)
JP2011517443A5 (https=)